Results 81 to 90 of about 71,065 (294)

Ameliorated in vitro anticancer efficacy of methotrexate d-α-Tocopheryl polyethylene glycol 1000 succinate ester against breast cancer cells

Future Journal of Pharmaceutical Sciences, 2019
Background Methotrexate (MTX), a folate anti-metabolite, has been used widely in the treatment of plenty of malignancies. However, the clinical use is limited because of its poor water solubility (BCS class II drug), nonspecific distribution, drug ...
Arehalli S. Manjappa, Popat S. Kumbhar, Rohini Kasabe, Sonali K. Diwate, John I. Disouza   +4 more
doaj   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen, Yangyi Wang, Tingting Li, Changqing Guo, Zhe Xie, Zhixian Zhang, Xinghua Han, Wei Wang, Jian Wang, Xiaopeng Ma, Yuanzeng Min   +10 more
wiley   +1 more source

Generalizable Strategies for the Synthesis of Cereblon‐Recruiting PROTAC Prodrugs

Angewandte Chemie, EarlyView.
Cereblon‐recruiting PROTACs remain challenging to derivatize for prodrug‐based delivery. In this study, three complementary conjugation strategies enabled the efficient synthesis of cleavable PROTAC prodrugs with tunable release kinetics that can be incorporated into a library of PEGylated constructs and bottlebrush prodrugs.
Aiden X. Wang, Bin Liu, Elise M. Ackerman, Yichen Xiang, Hung V.‐T. Nguyen, Yivan Jiang, Angela N. Koehler, Jeremiah A. Johnson   +7 more
wiley   +2 more sources

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses [PDF]

, 2012
Background: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011.
Hartley, J.A., MacPherson, I.R.J., Masanori Miwa, Hartley, JM, Jones, K, Crawford Donna, Saito Tomohisa, Evans, TRJ, Hartley, JA, Jones Keith, MacPherson, IRJ, Abe Masaichi, Crawford, D, Jones, K., D Alan Anthoney, John M Hartley, Saito, T., Twelves, C., Hartley Janet A, Anthoney, D.A., Christopher Twelves, Anthoney, DA, Miwa, M., Miwa Masanori, TRJ Evans, Evans, T.R.J., Naik, J, Jay Naik, Donna Crawford, Keith Jones, Abe, M., Saito, T, Tomohisa Saito, Abe, M, Naik Jay, Naik, J., MacPherson Iain RJ, Evans TRJ, Hartley, J.M., Hartley John M, Masaichi Abe, Miwa, M, Twelves, C, Crawford, D., Anthoney D, Janet A Hartley, Twelves Christopher, Iain RJ MacPherson   +47 more
core   +2 more sources

Photoactivated Platinum Complexes: Targeting Membrane Proteins and Organelles for Precision Cancer Therapy

Angewandte Chemie, EarlyView.
This review highlights an emerging anticancer approach integrating platinum agents into photodynamic therapy (PDT) and photoactivated chemotherapy (PACT) systems, further augmented by cancer cell membrane‐ and organelle‐targeting. By directing photoactivated platinum complexes from nontargeted distribution to cancer cells or defined subcellular sites ...
Shu Chen, Qiyuan Zhou, Jiaqian Xu, Guangyu Zhu   +3 more
wiley   +2 more sources

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

Advanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert, Christophe Nguyen, Sean Edward Dunn, Magali Gary‐Bobo, Jérôme Lacombe, Justin Moser, Frédéric Zenhausern, Jean‐Olivier Durand, Frédérique Cunin   +8 more
wiley   +1 more source

ALDH Inhibition‐Primed Photocatalysis Disrupts Cancer Stemness Plasticity

Angewandte Chemie, EarlyView.
DE‐Et converts ALDH‐mediated redox buffering into a photoredox vulnerability by coupling ALDH inhibition with red‐light‐driven catalytic NADH oxidation. This enzyme‐coupled photoredox strategy sustains mitochondrial NADH/NAD+ imbalance, induces pyroptotic tumor cell death, suppresses tumor growth in vivo, and promotes systemic antitumor immunity ...
Yujin Kim, Shankun Yao, Ji Hyeon Kim, Rongrong Huang, Hyeonji Rha, Shumeng Li, Kippeum Lee, Yunjie Xu, Xiaogang Liu, Yuncong Chen, Jong Seung Kim   +10 more
wiley   +2 more sources

N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool

Molecular Therapy: Nucleic Acids, 2020
MicroRNAs (miRNAs or miRs) play crucial roles in biological and pathological processes. Some miRNAs also appear as promising biomarkers and therapeutic tools. However, the epitranscriptomic regulation of miRNAs is not yet fully elucidated in all of their
Joséphine Briand, Aurélien A. Sérandour, Arulraj Nadaradjane, Gwenola Bougras-Cartron, Dominique Heymann, Benjamin Ory, François M. Vallette, Pierre-François Cartron   +7 more
doaj   +1 more source

Bioreversible Derivatization of Drug Molecules with a Pyridine Ring for Improved Water Solubility: Model Studies

A prodrug is a modified drug molecule having no significant biological activity but converts to the parent drug in the biological system. Conventionally, the prodrug is designed and synthesized by modifying a functional group that serves as a ‘synthetic ...
Bansal, Shubham
core   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source